Lite Strategy
San Diego-based MEI Pharma, Inc. develops novel oncology therapeutics targeting cancer metabolism for enhanced tumor cell inhibition.
Founded
2000San Diego-based MEI Pharma, Inc. develops novel oncology therapeutics targeting cancer metabolism for enhanced tumor cell inhibition.
Founded in San Diego, MEI Pharma, Inc. is dedicated to developing innovative oncology therapeutics that target cancer metabolism. The company's core mission is to enhance the inhibition of tumor cells through novel drug candidates that interact with specific enzyme targets critical for cancer cell survival. MEI Pharma's lead products are designed to disrupt the metabolic processes essential for cancer growth, focusing on providing new treatment options for patients battling various forms of cancer.
Notable figures associated with MEI Pharma include experienced professionals in oncology and pharmaceutical development. The company has achieved significant milestones, including promising initial data from clinical studies evaluating their drug candidates in combination with existing treatments like Bevacizumab (Avastin®). MEI Pharma's impact lies in its commitment to advancing cancer treatment through targeted metabolic disruption, offering hope for improved patient outcomes in the oncology field.
Companies similar to Lite Strategy include ImageneBio, Revolution Medicines, Innovo Therapeutics and Karyopharm Therapeutics.
Lite Strategy was founded in 2000.
Lite Strategy's headquarters is located in San Diego, CA, US.
Lite Strategy's most recent funding round was for $51.8M (USD) in December 2019.
As of Dec 19, 2019, Lite Strategy has disclosed funding of $160.4M (USD). Undisclosed round amounts are excluded.
Lite Strategy has 46 employees as of Feb 6, 2024.
Karyopharm Therapeutics
karyopharm.com
